A total of 250 Cardiologists (public sector and liberal sector) participate in the inclusion. The selection of patients eligible for inclusion and non-inclusion criteria will be made at the cardiology consultation level or during cardiology or emergencies hospitalizations. Any violation of the study protocol will be exposed to the Steering Committee which will decide on the exclusion of the patient in question. We included all outpatients with chronic HF (CHF) and those hospitalized for acute HF (AHF) de novo or not. No data were collected before the patient received detailed information and gave signed informed consent. Any selected patient will be introduced in the study and its explicit agreement will be solicited by signing an informed consent form. An ethical approval letter has been obtained from the ethic committee of the Abderrahmen Mami Pneumology and Phthisiology Hospital. The NATURE HF study has been submitted to and registered under the identifier NCT03262675. The protocol of the NATURE HF registry has been approved by the Tunisian Society of Cardiology and Cardiovascular Surgery. The NATURE- HF registry was a national, Tunisian, observational, longitudinal, prospective and multicentric registry carried out on a follow-up period of 13 months: 01 month of inclusion and 12 months of follow-up. The aims of the present study were to determine the epidemiological profile of acute and chronic HF patients, to assess the 1-year outcomes (death and rehospitalization) of patients with HF, and to identify prognostic predictors of these outcomes. The data of the European and United States populations cannot be extrapolated to the Tunisian population.
However, there is no extensive data available on demographic characteristics, prognosis and quality of care of patients with HF in Tunisia (nor in North Africa). In Tunisia and north-african countries, HF is a public health problem considering its current frequency and this is mainly linked to an aging of the Tunisian population (Africa’s oldest population, with the highest life expectancy of the continent) and an increase in coronary and hypertensive patients. In the United States and Europe, HF is responsible for a large proportion of morbi-mortality. It is estimated that 26 million people worldwide suffer from heart failure (HF). Data are available from the Tunisian Society of Cardiology and Cardiovascular Surgery Ethics Committee (contact via Résidence les pergolas, Rue du Lac Huron Appartement 201, Berges du Lac – Tunisie, Email: Tel: (+216) 71 965 432) for researchers who meet the criteria for access to confidential data.įunding: The authors received no specific funding for this work.Ĭompeting interests: The authors have declared that no competing interests exist. Indeed, data might reveal the identity and the location of participants included into the study. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.ĭata Availability: Data cannot be shared publicly because of privacy concern. Received: DecemAccepted: ApPublished: May 20, 2021Ĭopyright: © 2021 Abid et al. PLoS ONE 16(5):Įditor: Arman Kilic, University of Pittsburgh Medical Center, UNITED STATES (2021) Epidemiology of heart failure and long-term follow-up outcomes in a north-African population: Results from the NAtional TUnisian REgistry of Heart Failure (NATURE-HF). Some differences across countries may be due to different clinical characteristics and differences in healthcare systems.Ĭitation: Abid L, Charfeddine S, Kammoun I, Ben Halima M, Ben Slima H, Drissa M, et al. This study confirmed that acute HF is still associated with a poor prognosis, while the mid-term outcomes in patients with chronic HF seems to be improved. The female sex and the functional status were independent predictors of 1-year all-cause mortality and rehospitalization in AHF patients. Among CHF patients, the older age, diabetes, anemia, reduced EF, ischemic etiology, residual congestion and the absence of ACEI/ ARBs treatment were independent predictors of 1-year cumulative rates of rehospitalization and mortality. The all-cause 1-year mortality rate was 22.8% among AHF patients and 10.6% among CHF patients. The mortality rate during the initial hospitalization event for AHF was 7.4%. The mean hospital stay was 8.7 ± 8.2 days. Of these, 1632 (80%) were outpatients with chronic HF (CHF). A total of 2040 patients were included in the study.
This is a prospective, multicenter, observational survey conducted in Tunisian Cardiology centers. The NATURE-HF registry was aimed to describe clinical epidemiology and 1-year outcomes of outpatients and inpatients with heart failure (HF).
0 kommentar(er)
